IM Cannabis Corp. (NASDAQ:IMCC – Free Report) – Stock analysts at Roth Capital lowered their Q3 2024 earnings per share estimates for shares of IM Cannabis in a research note issued to investors on Thursday, August 15th. Roth Capital analyst S. Fortune now forecasts that the company will post earnings of ($1.36) per share for the quarter, down from their prior forecast of ($0.90). The consensus estimate for IM Cannabis’ current full-year earnings is ($4.32) per share. Roth Capital also issued estimates for IM Cannabis’ Q4 2024 earnings at ($1.15) EPS, FY2024 earnings at ($5.61) EPS, Q1 2025 earnings at ($0.93) EPS, Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($2.33) EPS.
IM Cannabis Stock Down 6.1 %
Shares of NASDAQ:IMCC opened at $2.77 on Monday. IM Cannabis has a 1 year low of $1.13 and a 1 year high of $8.10. The company has a market cap of $6.19 million, a PE ratio of -0.58 and a beta of 0.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.65 and a quick ratio of 0.40. The stock’s 50-day moving average is $2.70 and its 200 day moving average is $3.00.
Institutional Inflows and Outflows
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands.
Featured Stories
- Five stocks we like better than IM Cannabis
- NYSE Stocks Give Investors a Variety of Quality Options
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Bank Stocks – Best Bank Stocks to Invest In
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.